Lonza Signs Development and Manufacturing Agreement with Genmab

Lonza says it has signed a development and manufacturing agreement with biotechnology company Genmab (Copenhagen, Denmark) for a novel antibody drug conjugate (ADC), HuMax-TF. This agreement secures a development and cGMP manufacturing plan for Genmab to produce a novel ADC product targeting tissue factor (TF), a protein involved in tumor signalling and angiogenesis that is highly expressed on solid tumors, Lonza says. Lonza will initiate process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF at its Slough, U.K. facility. The...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers